# SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required)

Source: https://welltoldgrants.com/grants/par-23-220-sbir-sttr-commercialization-readiness-pilot-crp-program/  
Official notice: https://www.grants.gov/search-results-detail/349235

> National Institutes of Health offered grants to small businesses. Applications closed on September 5, 2025.

| Field | Value |
|---|---|
| Opportunity number | PAR-23-220 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | September 5, 2025 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.173, 93.233, 93.242, 93.273, 93.837, 93.838, 93.839, 93.840, 93.867 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following:Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

## What the grant funds

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The NOFO aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R and D throughout the award. This Notice of Funding Opportunity requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

## Questions people ask

### Is PAR-23-220 still open?

No. It closed on September 5, 2025.

### Who can apply for SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required)?

Closed September 5, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under PAR-23-220?

NIH RePORTER lists 7 projects funded under PAR-23-220 in fiscal 2024 to 2026, at 7 institutions. The most were at Linshom Medical Inc, Bridgesource Medical Corporation, Pascall Systems, Incorporated.

### Who has won Research Related to Deafness and Communication Disorders grants before?

The largest recipients over five fiscal years were The Johns Hopkins University, Massachusetts Eye and Ear Infirmary, The University of Iowa. The program made 2,231 awards worth $2.1 billion in that time.